Juan de Dios Caballero1, Rosa Del Campo1, Ana Royuela2, Amparo Solé3, Luis Máiz4, Casilda Olveira5, Esther Quintana-Gallego6, Javier de Gracia7, Marta Cobo8, Elia Gómez G de la Pedrosa1, Antonio Oliver9, Rafael Cantón10. 1. Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigaciones Sanitarias, Madrid, Spain; Red Española de Investigación en Patología Infecciosa (REIPI), Madrid, Spain. 2. CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Unidad de Bioestadística Clínica, Hospital Ramón y Cajal, IRYCIS, Madrid, Spain. 3. Unidad de Trasplante Pulmonar y Fibrosis Quística, Hospital Universitario y Politécnico La Fe, Valencia, Spain. 4. Servicio de Neumología, Hospital Universitario Ramón y Cajal, Madrid, Spain. 5. Servicio de Neumología, Hospital Regional Universitario de Málaga, Málaga, Spain. 6. Unidad de Fibrosis Quística. Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/Universidad de Sevilla, Sevilla, Spain; CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. 7. CIBER de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain; Department of Pulmonology, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, Spain. 8. Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigaciones Sanitarias, Madrid, Spain. 9. Red Española de Investigación en Patología Infecciosa (REIPI), Madrid, Spain; Servicio de Microbiología y Unidad de Investigación, Hospital Universitario Son Espases and Instituto de Investigación Sanitaria de Palma (IdISPa), Palma de Mallorca, Spain. 10. Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigaciones Sanitarias, Madrid, Spain; Red Española de Investigación en Patología Infecciosa (REIPI), Madrid, Spain. Electronic address: rafael.canton@salud.madrid.org.
Abstract
BACKGROUND: Clinical and demographical knowledge on Spanish cystic fibrosis (CF) patients is incomplete as no national registry exists. CF-microbiology has not been studied at national level. The results of the first Spanish multicenter study on CF microbiology are presented. METHODS: 24 CF-Units for adult (n=12) and pediatric (n=12) patients from 17 hospitals provided sputa and clinical data from 15 consecutive patients. Cultures and susceptibility testing were performed. Colonization impact on pulmonary function was assessed. RESULTS: 341 patients [mean (SD) age 21 (11) years, 180≥18years, mean (SD) FEV1=68 (25)%] were included. Pseudomonas aeruginosa was reported as chronic, intermittent or absent in 46%, 22% and 32% of patients, respectively. The annual prevalence was 62%. Positive P. aeruginosa and methicillin-resistant Staphylococcus aureus cultures were significantly associated with lower FEV1 (p<0.001 and p=0.003, respectively). CONCLUSIONS: The representative subset of the Spanish CF-population which has been clinically, demographically and microbiologically characterized will serve as a reference for future CF studies in Spain.
BACKGROUND: Clinical and demographical knowledge on Spanish cystic fibrosis (CF) patients is incomplete as no national registry exists. CF-microbiology has not been studied at national level. The results of the first Spanish multicenter study on CF microbiology are presented. METHODS: 24 CF-Units for adult (n=12) and pediatric (n=12) patients from 17 hospitals provided sputa and clinical data from 15 consecutive patients. Cultures and susceptibility testing were performed. Colonization impact on pulmonary function was assessed. RESULTS: 341 patients [mean (SD) age 21 (11) years, 180≥18years, mean (SD) FEV1=68 (25)%] were included. Pseudomonas aeruginosa was reported as chronic, intermittent or absent in 46%, 22% and 32% of patients, respectively. The annual prevalence was 62%. Positive P. aeruginosa and methicillin-resistant Staphylococcus aureus cultures were significantly associated with lower FEV1 (p<0.001 and p=0.003, respectively). CONCLUSIONS: The representative subset of the Spanish CF-population which has been clinically, demographically and microbiologically characterized will serve as a reference for future CF studies in Spain.
Authors: Miquel B Ekkelenkamp; Rafael Cantón; María Díez-Aguilar; Michael M Tunney; Deirdre F Gilpin; Francesca Bernardini; Glenn E Dale; J Stuart Elborn; Jumamurat R Bayjanov; Ad Fluit Journal: Antimicrob Agents Chemother Date: 2020-01-27 Impact factor: 5.191
Authors: María Díez-Aguilar; María Isabel Morosini; Emin Köksal; Antonio Oliver; Miquel Ekkelenkamp; Rafael Cantón Journal: Antimicrob Agents Chemother Date: 2017-12-21 Impact factor: 5.191
Authors: Juan de Dios Caballero; María Dolores Pastor; Ana Vindel; Luis Máiz; Genoveva Yagüe; Carme Salvador; Marta Cobo; María-Isabel Morosini; Rosa del Campo; Rafael Cantón Journal: Antimicrob Agents Chemother Date: 2015-12-14 Impact factor: 5.191
Authors: Jesse R Willis; Ester Saus; Susana Iraola-Guzmán; Elena Cabello-Yeves; Ewa Ksiezopolska; Luca Cozzuto; Luis A Bejarano; Nuria Andreu-Somavilla; Miriam Alloza-Trabado; Andrea Blanco; Anna Puig-Sola; Elisabetta Broglio; Carlo Carolis; Julia Ponomarenko; Jochen Hecht; Toni Gabaldón Journal: J Oral Microbiol Date: 2021-05-17 Impact factor: 5.474
Authors: Ad C Fluit; Jumamurat R Bayjanov; María Díez Aguilar; Rafael Cantón; Stuart Elborn; Michael M Tunney; Jelle Scharringa; Barry J Benaissa-Trouw; Miquel B Ekkelenkamp Journal: BMC Microbiol Date: 2022-05-12 Impact factor: 4.465
Authors: Marta Garcia-Clemente; David de la Rosa; Luis Máiz; Rosa Girón; Marina Blanco; Casilda Olveira; Rafael Canton; Miguel Angel Martinez-García Journal: J Clin Med Date: 2020-11-24 Impact factor: 4.241